NanoViricides, Inc. NEW (NNVC): Price and Financial Metrics


NanoViricides, Inc. NEW (NNVC): $2.15

0.08 (+3.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NNVC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NNVC Stock Price Chart Interactive Chart >

Price chart for NNVC

NNVC Price/Volume Stats

Current price $2.15 52-week high $7.86
Prev. close $2.07 52-week low $1.04
Day low $2.09 Volume 115,400
Day high $2.25 Avg. volume 66,193
50-day MA $1.84 Dividend yield N/A
200-day MA $3.25 Market Cap 24.84M

NanoViricides, Inc. NEW (NNVC) Company Bio


NanoViricides, Inc. is a biopharmaceutical company. The Company researches treatments for viruses such as AIDS/HIV, Hepatitis C, influenza, and Asian bird flu.


NNVC Latest News Stream


Event/Time News Detail
Loading, please wait...

NNVC Latest Social Stream


Loading social stream, please wait...

View Full NNVC Social Stream

Latest NNVC News From Around the Web

Below are the latest news stories about Nanoviricides Inc that investors may wish to consider to help them evaluate NNVC as an investment opportunity.

NanoViricides (NYSEAMERICAN:NNVC) Issues Earnings Results

NanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of []

Dakota Financial News | November 18, 2021

NanoViricides, Inc. (NYSEAMERICAN:NNVC) Short Interest Update

NanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 []

Transcript Daily | November 18, 2021

NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n

FinanzNachrichten | November 16, 2021

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission.

Yahoo | November 16, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | November 15, 2021

Read More 'NNVC' Stories Here

NNVC Price Returns

1-mo 34.38%
3-mo 7.50%
6-mo -54.35%
1-year -40.11%
3-year -57.00%
5-year -92.21%
YTD -42.20%
2021 29.62%
2020 14.34%
2019 -37.25%
2018 -77.27%
2017 -17.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4179 seconds.